European Health Summit 2026

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Health technology assessment (HTA)

Structured evaluation of a medicine, device or diagnostic that compares clinical benefit and cost against existing care, used by payers to decide coverage and price.

2

EU HTA Regulation and joint clinical assessment (JCA)

The EU framework under which member states assess certain new medicines and high-risk devices once at EU level, with national bodies then deciding price and reimbursement locally. A recurring theme for pharma and medtech delegates at Brussels health-policy meetings.

3

European Health Data Space (EHDS)

EU rules on sharing and secondary use of health data, covering patient access, cross-border exchange and research use under common safeguards. Relevant to hospitals, registries and real-world evidence teams.

4

Real-world evidence (RWE)

Evidence generated from routine care - registries, claims, electronic health records - rather than randomised trials, increasingly used to support label extensions and reimbursement dossiers.

5

Value-based healthcare

Payment and delivery models that tie funding to measured outcomes per patient or per condition instead of volume of procedures, a common payer talking point in Brussels.

6

Medical Device Regulation (MDR) and IVDR

EU rules governing market access for medical devices and in-vitro diagnostics, including clinical evidence and notified-body review. Frequently discussed alongside reimbursement pathways for medtech.

7

Market access

The work of getting a product reimbursed and adopted: pricing, HTA submission, payer negotiation and hospital formulary listing.

8

Horizon Europe health cluster

The EU research funding stream covering health challenges, including cancer, pandemic preparedness and digital health, often referenced by academic and SME delegates.

9

Pandemic preparedness and HERA

EU-level planning for medical countermeasures, surveillance and manufacturing capacity, coordinated through the European Health Emergency Preparedness and Response Authority.

10

Digital therapeutics and DTx reimbursement

Software-delivered treatments that need their own evidence and payment route, often through national digital health frameworks rather than classic drug pricing.

11

European Reference Networks (ERNs)

Cross-border networks of specialised centres for rare and complex diseases, relevant to clinicians and rare-disease patient advocates attending Brussels health events.

12

Cross-border healthcare directive

EU rules allowing patients to seek treatment in another member state and claim reimbursement at home, a longstanding topic in patient-access debates.